Zhejiang Huakang Pharmaceutical Co Ltd
Zhejiang Huakang Pharmaceutical Co., Ltd. engages in the research, production, and sale of polyols and starch sugar worldwide. It offers polyols products such as xylitol, is a polyol that occurs naturally regular sugar raise blood sugar levels; sorbitol, is produced by the catalytic hydrogenation of D-glucose and is available as a free-flowing crystalline powder, and as aqueous solutions; maltito… Read more
Zhejiang Huakang Pharmaceutical Co Ltd (605077) - Total Assets
Latest total assets as of June 2025: CN¥7.56 Billion CNY
Based on the latest financial reports, Zhejiang Huakang Pharmaceutical Co Ltd (605077) holds total assets worth CN¥7.56 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zhejiang Huakang Pharmaceutical Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Zhejiang Huakang Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zhejiang Huakang Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Huakang Pharmaceutical Co Ltd's total assets of CN¥7.56 Billion consist of 36.8% current assets and 63.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.2% |
| Accounts Receivable | CN¥682.32 Million | 9.8% |
| Inventory | CN¥697.39 Million | 10.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥305.87 Million | 4.4% |
| Goodwill | CN¥346.16 Million | 5.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Zhejiang Huakang Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Huakang Pharmaceutical Co Ltd's current assets represent 36.8% of total assets in 2024, a decrease from 44.3% in 2016.
- Cash Position: Cash and equivalents constituted 6.2% of total assets in 2024, down from 9.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 5.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 10.0% of total assets.
Zhejiang Huakang Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Huakang Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fauji Fertilizer Bin Qasim Ltd
KAR:FFBL
|
Pakistan | PKRs203.28 Billion |
|
Yunnan Yunwei Co Ltd Class A
SHG:600725
|
China | CN¥345.43 Million |
|
Rifa Ind
KO:000760
|
Korea | ₩270.50 Billion |
|
North Huajin Chemical Industries Co Ltd
SHE:000059
|
China | CN¥24.47 Billion |
|
Sichuan Chemical Co Ltd
SHE:000155
|
China | CN¥28.26 Billion |
|
Jiangsu Wujiang China Eastern Silk Market Co Ltd
SHE:000301
|
China | CN¥212.80 Billion |
|
Zangge Holding Co Ltd
SHE:000408
|
China | CN¥16.36 Billion |
|
Sichuan Jinlu Group Co Ltd
SHE:000510
|
China | CN¥2.53 Billion |
Zhejiang Huakang Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Zhejiang Huakang Pharmaceutical Co Ltd generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Zhejiang Huakang Pharmaceutical Co Ltd generates $ 3.84 in net profit.
Zhejiang Huakang Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.65 | 2.23 | 1.63 |
| Quick Ratio | 1.24 | 1.88 | 1.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.21 Billion | CN¥ 1.33 Billion | CN¥ 220.84 Million |
Zhejiang Huakang Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Huakang Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.49 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 13.2% |
| Total Assets | CN¥6.99 Billion |
| Market Capitalization | $301.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Huakang Pharmaceutical Co Ltd's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Zhejiang Huakang Pharmaceutical Co Ltd's assets grew by 13.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Zhejiang Huakang Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual total assets of Zhejiang Huakang Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.99 Billion | +13.18% |
| 2023-12-31 | CN¥6.18 Billion | +58.20% |
| 2022-12-31 | CN¥3.91 Billion | +29.99% |
| 2021-12-31 | CN¥3.00 Billion | +110.12% |
| 2020-12-31 | CN¥1.43 Billion | +23.89% |
| 2019-12-31 | CN¥1.15 Billion | +10.10% |
| 2018-12-31 | CN¥1.05 Billion | +49.27% |
| 2017-12-31 | CN¥702.16 Million | +2.94% |
| 2016-12-31 | CN¥682.12 Million | -- |